European IP

Case law

Dosage regimen patents at the EPO part (II): Recent case law

Dosage regimen patent applications are typically filed a few years after the original application to compounds and their medical uses. Often a clinical trial will already be underway, investigating di...

"A genuine commitment to understanding their clients’ business objectives and consistently providing valuable strategic insights" - Kilburn & Strode retains double gold ranking in IAM Patent 1000

Kilburn & Strode has been awarded gold in both the UK and European Patent Office categories, as well as bronze in The Netherlands, in this year’s IAM Patent 1000.

News

Kilburn & Strode recognised by MIP as tier 1 for Trade Mark prosecution

Kilburn & Strode is proud to have once again been recognised as a tier 1 firm for trade mark prosecution in the 2025 edition of IP Stars, from Managing IP.

Technical Tips

Dosage regimen patents at the EPO part (I): Strategic tips for success

Dosage regimen claims typically refer to compounds for use in treating a condition at a specific frequency of administration, at a specific dose or within a specific dosage range. Sometimes further fe...

Case law

Challenges of extending expired patent rights through trade marks in the medical implant market: Insights from AG Biondi’s Opinion in Case C-17/24

Trade marks can offer very powerful complementary and long-lasting benefits for companies once their patents expire. The term of protection of a patent can give its owner a precious period in which to...

Thoughts

How RNA therapeutics are shaping the future of mental health treatment

This Mental Health Awareness Week, we wanted to highlight how the fast-moving field of RNA therapeutics is being leveraged to treat mental health disorders such as anxiety and depression. We will cove...

Thoughts

Opposition Hotspots: Which medical technology sectors face the highest rate of EPO opposition?

Which MedTech sectors see the most oppositions at the EPO? Which MedTech patents are safer from being revoked or limited via EPO opposition?

Thoughts

Can “public prior use” be relied upon to invalidate European patents?

The “state of the art” for assessing novelty and inventive step at the European Patent Office includes “…everything made available to the public by means of a written or oral description, by use, or i...

Thoughts

LNPs: Small lipids, big potential in nucleic acid delivery

Lipid nanoparticles (LNPs) have emerged as a leading pharmaceutical formulation technology, particularly for nucleic acid delivery.